AI Article Synopsis
- Castration-resistant prostate cancer has shifted focus from being hormone-resistant to showing resistance to androgen deprivation therapy over the past decade.
- New treatments targeting the androgen receptor have proven effective for patients with worsening castration-resistant prostate cancer.
- The review discusses the molecular mechanisms that play a role in the development of castration-resistant prostate cancer, highlighting the continued importance of the androgen receptor in this condition.
Article Abstract
Castration-resistant prostate cancer was subjected to a paradigm switch from hormone resistance to androgen deprivation therapy resistance during the last decade. Indeed, new therapeutics targeting the androgen receptor showed clinical efficacy in patients with progressive disease under castration. Thus, it is a proof that the AR remains a dominant driver of oncogenesis in earlier-called hormone resistant prostate cancer. This review summarizes the molecular mechanisms involved in castration-resistant prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2015.04.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and Validation of Alkaliptosis Resistance-Associated Genes in Prostate Cancer Via Transcriptome Sequencing and Prediction of Biochemical Recurrence.
Mol Biotechnol
January 2025
Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Androgen deprivation therapy (ADT) is the primary treatment strategy for prostate cancer. However, despite an initially favorable response, tumors inevitably progress to castration-resistant prostate cancer (CRPC). Therefore, the exploration of new therapeutic approaches targeting CRPC has become imperative.
View Article and Find Full Text PDFClinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target.
Mol Ther Oncol
December 2024
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Prostate cancer (PCa) is the second most common cancer among men worldwide. The main screening tool remains the prostate-specific antigen (PSA), which shows significant limitations, including poor sensitivity/specificity. Therefore, establishing accurate non-invasive diagnostic biomarkers remains an unmet clinical need in PCa.
View Article and Find Full Text PDFCurrent Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis.
Cancer Diagn Progn
January 2025
Department of Urology, Showa University School of Medicine, Tokyo, Japan.
Background/aim: Although multiple treatments are available for metastatic castration-resistant prostate cancer, data to determine the optimal treatment sequence are limited. This study aimed to investigate the current status of drug therapy for castration-resistant prostate cancer and clarify the sequential treatment in actual clinical practice.
Patients And Methods: This retrospective study included 425 patients diagnosed with castration-resistant prostate cancer at Showa University Hospital and affiliated hospitals between January 2014 and December 2021, who were treated with any of the following four drugs: novel androgen receptor signal inhibitors (abiraterone acetate and enzalutamide) and anticancer drugs (docetaxel and cabazitaxel).
Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A Systematic Review and Meta-analysis.
Acad Radiol
January 2025
University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network-Sinai Health System -Women's College Hospital, University of Toronto, Toronto, ON, Canada (S.A.M., P.V.H., U.M., A.B.D.). Electronic address:
Rationale And Objectives: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0).
View Article and Find Full Text PDFSystems-level liquid biopsy in advanced prostate cancer.
Endocr Relat Cancer
January 2025
S Dehm, Masonic Cancer Center, University of Minnesota, Minneapolis, United States.
Treatment for castration-resistant prostate cancer (CRPC) primarily involves the suppression of androgen receptor (AR) activity using androgen receptor signaling inhibitors (ARSIs). While ARSIs have extended patient survival, resistance inevitably develops. Mechanisms of resistance include genomic aberrations at the AR locus that reactivate AR signaling, or lineage plasticity that drives emergence of AR-independent phenotypes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!